The Immunomodulator FTY720 Has a Direct Cytoprotective Effect in Oligodendrocyte Progenitors
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 2×
“, 2004) have shown that ERK has a protective effect against apoptotic cell death of OLGs induced by reactive oxygen species, known to be produced by activated microglia (Block et al., 2007).”
BackgroundMultiple extracellular signals are required for long-term oligodendrocyte survival
Barres, B. A., Schmid, R., Sendnter, M., & Raff, M. C. (1993) · Development · doi:10.1242/dev.118.1.283 · Cited by 712
Fragoso, G., Martínez‐Bermúdez, A. K., Liu, H., Khorchid, A., Chemtob, S., Mushynski, W. E., & Almazan, G. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02488.x · Cited by 82 · cited 3×
“The ERK1/2 and PI3K/Akt signaling pathways have been implicated in promoting OLG survival under different conditions (Ebner et al., 2000; Fragoso et al., 2004; Cui et al., 2006).”
BackgroundStem cells, progenitors and myelin repair
Zhao, C., Fancy, S. P. J., Magy, L., Urwin, J. E., & Franklin, R. J. M. (2005) · Journal of Anatomy · doi:10.1111/j.1469-7580.2005.00456.x · Cited by 61
Cited by
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
“Fingolimod exposure in vitro has also been reported to increase the number of both progenitor and mature oligodendrocytes, to protect oligodendrocytes from cell death induced by cytokines or the withdrawal of growth factors, and to modulate process outgrowth (both retraction and extension).(59,101,102) The effects of…”
BackgroundMechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Bar-Or, A., Pachner, A., Menguy-Vacheron, F., Kaplan, J., & Wiendl, H. (2014) · Drugs · doi:10.1007/s40265-014-0212-x · Cited by 356
Metadata
- Authors
- Coelho, R. P., Payne, S. G., Bittman, R., Spiegel, S., & Sato-Bigbee, C.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 323
- Issue
- 2
- Pages
- 626-635
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2144958446
- Cited by
- 175
- References
- 5
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.